LOGIN  |  REGISTER

PacBio (NASDAQ: PACB) Stock Quote

Last Trade: US$1.87 -0.07 -3.61
Volume: 7,969,210
5-Day Change: -14.61%
YTD Change: -80.94%
Market Cap: US$509.310M

Latest News From PacBio

Consortium Selects Leading Genomics Companies to Support Pediatric Mendelian Genomics Research Center Program ALISO VIEJO, Calif. and MENLO PARK, Calif. , May 15, 2024 /PRNewswire/ -- Ambry Genetics , a prominent leader in clinical genomic testing and a subsidiary of REALM IDx, Inc., along with PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced their companies'... Read More
MENLO PARK, Calif. , May 9, 2024 /PRNewswire/ -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended March 31, 2024 . First quarter results: Revenue of $38.8 million compared with $38.9 million in the prior-year period. Instrument revenue of $19.0 million compared with $20.7 million in the prior-year period. Instrument revenue in the first quarter of 2024 included 28 Revio TM sequencing systems.... Read More
Announces Plan to Reduce Annualized Operating Expense Run Rate by $50 - $75 Million Q1 2024 Earnings Conference Call Scheduled for May 9, 2024 MENLO PARK, Calif. , April 16, 2024 /PRNewswire/ – PacBio (NASDAQ: PACB) today announced preliminary, unaudited revenue for the quarter ended March 31, 2024. Preliminary First Quarter Results Preliminary revenue of $38.8 million , roughly flat compared with $38.9 million in the... Read More
HiFi Data Generated on the Revio™ System will Support the EU and Estonian Government-Funded Center for Personalized Medicine and Unlock Discoveries Across Cardiology, Mental and Reproductive Health, Drug Response, Cancer Research and Rare Diseases MENLO PARK, Calif. , March 27, 2024 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced that the... Read More
MENLO PARK, Calif. , March 22, 2024 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading provider of high-quality, highly accurate sequencing platforms, today announced that the Compensation Committee of the Company's Board of Directors granted a non-qualified stock option (the "Option") covering an aggregate of 79,600 shares of PacBio common stock and restricted stock units ("RSUs") covering 39,800 shares of PacBio common stock... Read More
HiFi Long-Read Sequencing Panel Supports Comprehensive Analysis of 20 Genes Associated With Neurological Disease MENLO PARK, Calif. , March 12, 2024 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the PureTarget repeat expansion panel, a new solution designed to enable the comprehensive analysis of 20 genes associated with serious neurological... Read More
MENLO PARK, Calif. , Feb. 26, 2024 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will be participating in the following upcoming investor conferences: TD Cowen 44th Annual Health Care Conference on Tuesday, March 5, 2024 , at 1:30 PM ET in Boston, MA Barclays 26th Annual Global Healthcare Conference on Tuesday, March 12, 2024... Read More
MENLO PARK, Calif. , Feb. 15, 2024 /PRNewswire/ -- PacBio (NASDAQ: PACB) today announced financial results for the quarter and fiscal year ended December 31, 2023. Fourth quarter results Revenue of $58.4 million , a 113% increase compared with $27.4 million in the prior-year period. Instrument revenue of $35.1 million compared with $6.1 million in the prior-year period. Consumables revenue of $18.9 million compared with... Read More
ATLANTA , Feb. 13, 2024 /PRNewswire/ -- VOLO Events Agency (VOLO), a leading producer of experiential marketing and live events for global brands, has won the best Event Technology award at the BizBash 11th Annual Event Experience Awards. The award recognizes the outstanding use of technology to create an immersive and engaging event experience for PacBio (NASDAQ: PACB) a pioneering leader in the Biotechnology industry. The... Read More
New Library Preparation Solutions Offer Never Before Achieved Scale for the Revio™ Sequencing System MENLO PARK, Calif. , Feb. 5, 2024 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced two new high throughput library preparation kits and workflows optimized for its Revio sequencing system. With these kits, PacBio takes another leap forward in the... Read More
MENLO PARK, Calif. , Jan. 25, 2024 /PRNewswire/ -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its fourth quarter 2023 financial results on Thursday, February 15, 2024 , at 5:00 pm Eastern Time . The call will be webcast and may be accessed at PacBio's website at: https://investor.pacificbiosciences.com/ . Date: Thursday, February 15, 2024 , at 5:00 pm ET ( 2:00 pm PT )... Read More
Existing HT CBB Kit Enables High-Throughput Extraction of HMW DNA Tailored for HiFi With an Updated Workflow for Animal Blood and Bacteria MENLO PARK, Calif. , Jan. 15, 2024 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced PanDNA, a versatile Nanobind DNA extraction kit. This new offering expands the array of sample types suitable for long-read... Read More
Ships a record number of PacBio sequencers in 2023, including 173 Revio™ systems, and announces record fourth quarter preliminary consumable revenue of $18.9 million as demand for long-read sequencing grows and increased capacity from the Revio system drives sample elasticity MENLO PARK, Calif. , Jan. 8, 2024 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions,... Read More
MENLO PARK, Calif. , Dec. 27, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will be presenting at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024 , at 1:30 PM PT ( 4:30 PM ET ) in San Francisco, California . A live webcast of the event can be accessed at the company's investors page at... Read More
MENLO PARK, Calif. , Dec. 11, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that David Botstein , Ph.D., a member of PacBio's Board of Directors, has retired from his position effective December 7, 2023 . "I would like to thank David for his dedication to PacBio since he joined the Board in 2012," said Christian Henry , President and... Read More
MENLO PARK, Calif. , Nov. 9, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will be participating in the following upcoming investor conferences: Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on Thursday, November 16, 2023 , at 2:00 PM ET in New York, NY Piper Sandler 35th Annual Healthcare... Read More
Consortium Aims to Share Best Practices and Increase our Understanding of Genetic Disease MENLO PARK, Calif. , Nov. 2, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the creation of the HiFi Solves consortium. This global consortium brings together researchers from 15 leading genomics research institutions across 11 countries to study the... Read More
Partnerships Maximize Value of HiFi Data and Complete the Full End-to-End Workflow for PacBio Customers. MENLO PARK, Calif. , Nov. 1, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the addition of two tertiary analysis partners to PacBio Compatible. Geneyx and Golden Helix will enable PacBio customers to leverage PacBio HiFi data for... Read More
Building on the MAS-Seq Concatenation Method, These Three New Kits can Significantly Increase Throughput in RNA Applications MENLO PARK, Calif. , Oct. 31, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced it has begun taking orders for its groundbreaking Kinnex RNA kits, which increase throughput for full-length RNA, single-cell RNA, and 16S... Read More
MENLO PARK, Calif. , Oct. 30, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended September 30, 2023 . Third quarter results Revenue of $55.7 million , a 72% increase compared with $32.3 million in the prior-year period. Instrument revenue of $34.7 million compared with $11.4 million in the prior-year period. Instrument revenue in the third quarter of 2023 included revenue... Read More
Former CFO of Moderna, Amgen, and 3M Brings Decades of Relevant Experience to the PacBio Board MENLO PARK, Calif. , Oct. 16, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the appointment of David Meline to its Board of Directors, effective October 13, 2023 . Mr. Meline was most recently the Chief Financial Officer of Moderna, Inc., a... Read More
MENLO PARK, Calif. , Oct. 12, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its third quarter 2023 financial results on Monday, October 30, 2023 , at 4:30 pm Eastern Time . The call will be webcast and may be accessed at PacBio's website at: https://investor.pacificbiosciences.com/ . Date: Monday, October 30, 2023 , at 4:30 pm ET ( 1:30 pm PT ) Listen... Read More
PacBio WGS Variant Pipeline Will Bring Standardization to PacBio HiFi Data Analysis MENLO PARK, Calif. , Oct. 11, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the availability of PacBio WGS Variant Pipeline – a complete, standardized computational method for HiFi whole genome sequencing (WGS) data analysis. The new software pipeline... Read More
New Program Expands Access to PacBio's Highly Accurate Sequencing Systems by Providing Flexible Financing MENLO PARK, Calif. , Sept. 12, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced PacBio Capital, a program that offers customers the ability to lease PacBio sequencing systems – Revio, Onso and Sequel IIe – easily and cost-effectively.... Read More
Hamilton, Integra, Revvity, and Tecan Join PacBio Compatible to Offer Verified Automated Library Prep Workflows for Whole Genome Sequencing MENLO PARK, Calif. , Sept. 7, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced that automation providers Hamilton, Integra, Revvity and Tecan have created fully automated protocols to prepare samples... Read More
MENLO PARK, Calif. , Aug. 9, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will be participating in the following upcoming investor conferences: UBS MedTech, Tools and Genomics Summit 2023 on Wednesday, August 16, 2023 , at 4:00 PM PT in Dana Point, CA Morgan Stanley 21st Annual Global Healthcare Conference on Tuesday,... Read More
Study is first of its kind to compare diagnostic rates across short- and long-read sequencing platforms MENLO PARK, Calif. and STAMFORD, Conn. , Aug. 7, 2023 /PRNewswire/ -- PacBio (Nasdaq: PACB), a leading developer of high-quality, highly accurate sequencing solutions and GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced a research collaboration... Read More
MENLO PARK, Calif. , Aug. 4, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced that PacBio's Compensation Committee of the Board of Directors granted non-qualified stock options covering an aggregate of 100,000 shares of PacBio common stock and restricted stock units ("RSUs") covering 184,700 shares of PacBio common stock to fourteen... Read More
MENLO PARK, Calif. , Aug. 2, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended June 30, 2023 . Second quarter results Revenue of $47.6 million , a 34% increase compared with $35.5 million in the prior year-period. Recognized revenue on 47 sequencing systems in the second quarter, including 45 Revio systems and 2 Sequel IIe systems, compared to 36 Sequel II/IIe systems in the... Read More
PacBio will Combine Apton's Proprietary Sequencing Technology With its Highly Accurate Sequencing by Binding Chemistry to Develop a High-Throughput Sequencer Designed to Deliver Billions of Reads per Flow Cell MENLO PARK, Calif. , Aug. 2, 2023 /PRNewswire/ -- PacBio , a leading developer of high-quality, highly accurate sequencing solutions, today announced that it has entered into an agreement to acquire Apton Biosystems,... Read More
HealthStocksHub
The Onso Platform Delivers Extraordinary Accuracy Which Creates New Possibilities for Research and Translational Sequencing Applications MENLO PARK, Calif. , Aug. 2, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced that customer shipments of Onso... Read More
MENLO PARK, Calif. , July 19, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its second quarter 2023 financial results on Wednesday, August 2, 2023 , at 5:00 pm Eastern Time . The call will be webcast and may be accessed at PacBio's website at: https://investor.pacificbiosciences.com/ . Date: Wednesday, August 2, 2023 , at 5:00 pm ET ( 2:00 pm PT ) Listen... Read More
Bioscientia Acquires Multiple Revio Sequencing Systems to Revolutionize Rare Disease Research by Sequencing Thousands of Long-Read Human Genomes Annually MENLO PARK, Calif. , June 28, 2023 /PRNewswire/ -- PacBio , a leading developer of high-quality, highly accurate sequencing solutions, today announced that Bioscientia is using its Revio long-read sequencing systems to expand its genomics research projects and sequence... Read More
MENLO PARK, Calif. , June 26, 2023 /PRNewswire/ -- Pacific Biosciences of California , Inc. (" PacBio ") (NASDAQ: PACB) today announced that it has entered into a privately negotiated exchange agreement with a holder of PacBio's outstanding 1.50% Convertible Senior Notes due 2028 (the " 2028 Notes "), pursuant to which PacBio will issue $441 million principal amount of its 1.375% Convertible Senior Notes due 2030 (the " New... Read More
Collaboration Aims to Show Utility and Cost Effectiveness of HiFi Sequencing in Clinical Research Settings, Using Revio Systems MENLO PARK, Calif. , June 14, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions today announced a clinical research study with Radboud University Medical Center (Radboudumc) to explore genetic causes of rare and genetic diseases.... Read More
Current Member, Jay Shendure , is Appointed Chair MENLO PARK, Calif. , May 30, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the appointment of Olga Troyanskaya , Ph.D., Professor of Computer Science and the Lewis Sigler Institute for Integrative Genomics at Princeton University to PacBio's Scientific Advisory Board (SAB) and Jay... Read More
MENLO PARK, Calif. , May 25, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that it will be participating in the following upcoming investor conferences: Bernstein's 39th Annual Strategic Decisions Conference on Thursday, June 1, 2023 , at 2:30 PM ET in New York, NY Goldman Sachs 44th Annual Global Healthcare Conference on Tuesday, June... Read More
MENLO PARK, Calif. , May 3, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that it will be participating in the BofA Securities 2023 Health Care Conference in Las Vegas, Nevada . PacBio management is scheduled to participate in a fireside chat on Wednesday, May 10th, 2023 , at 9:20 am Pacific Time . Interested parties may access a live... Read More
MENLO PARK, Calif. , May 2, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended March 31, 2023 . First quarter results Revenue of $38.9 million , a 17% increase compared with $33.2 million in the prior year period. Shipped 38 sequencing systems in the first quarter, including 32 Revio systems and 6 Sequel IIe systems. Instrument revenue of $20.7 million compared with $15.6... Read More
MENLO PARK, Calif. , April 18, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its first quarter 2023 financial results on Tuesday, May 2, 2023 , at 4:30 pm Eastern Time . The call will be webcast and may be accessed at PacBio's website at: https://investor.pacificbiosciences.com/ . Date: Tuesday, May 2, 2023 at 4:30 pm ET ( 1:30 pm PT ) Listen live via... Read More
HealthStocksHub
Kits Combine the Power of HiFi Sequencing and Nanobind Technology to Optimize Sample Preparation Workflows for High Volume Customers MENLO Park, Calif. , April 5, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the availability of its new... Read More
MENLO PARK, Calif. , March 28, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced new workflows developed with global agriculture company, Corteva Agriscience that enable high throughput plant and microbial genome sequencing. This collaboration, which originated at the Advances in Genome Biology and Technology (AGBT) Agricultural meeting last... Read More
Paraphase Enables Researchers to Analyze Genes That are Critically Relevant but Hard to Genotype MENLO PARK, Calif. , March 14, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of highly accurate sequencing solutions, today announced a new informatics method that genotypes gene paralogs and pseudogenes with high accuracy. The new computational tool, named "Paraphase," enables variant calling, copy number... Read More
HealthStocksHub
Broad Commercialization and Scale-Up of Revio Enables Researchers with 15 Times More HiFi Data and High-Quality Human Genomes for Under $1,000 MENLO PARK, Calif. , March 7, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the first customer... Read More
MENLO PARK, Calif. , Feb. 27, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that it will be participating in Cowen's 43rd Annual Health Care Conference in Boston, Massachusetts . PacBio management is scheduled to participate in a fireside chat on Tuesday, March 7th at 12:50 PM ET . Interested parties may access a live and archived... Read More
MENLO PARK, Calif. , Feb. 16, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB) today announced financial results for the quarter and fiscal year ended December 31, 2022 . Fourth quarter results Received record orders in the fourth quarter, including orders for 96 instruments, which included orders for 76 Revio systems from 43 customers across 13 countries and representing a broad set of applications. Revenue of $27.4 million , a... Read More
End-to-End Solutions Planned to Support Key Customer Applications With Increased Cost Flexibility on Long-Read Sequencing Systems MENLO PARK, Calif. , Feb. 7, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the commencement of a program intended to expand Multiplexed Arrays Sequencing (MAS-Seq) for new assays on the Sequel II/IIe and... Read More
MENLO PARK, Calif. , Feb. 2, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its fourth quarter and full year 2022 financial results on Thursday, February 16, 2023 , at 4:30 pm Eastern Time . The call will be webcast and may be accessed at PacBio's website at: https://investor.pacificbiosciences.com/ . Date: Thursday, February 16, 2023 at 4:30 pm ET ( 1:30... Read More
MENLO PARK, Calif. , Jan. 24, 2023 /PRNewswire/ -- Pacific Biosciences of California , Inc. (Nasdaq: PACB) ("PacBio") today announced that it has priced its previously announced underwritten public offering of 17,500,000 shares of its common stock at a price to the public of $10.00 per share. PacBio has granted the underwriters a 30-day option to purchase up to an additional 2,625,000 shares of its common stock at the public... Read More
MENLO PARK, Calif. , Jan. 24, 2023 /PRNewswire/ -- Pacific Biosciences of California , Inc. (Nasdaq: PACB) ("PacBio") today announced that it intends to offer and sell $150.0 million of shares of its common stock in an underwritten public offering. PacBio also intends to grant the underwriters a 30-day option to purchase up to an additional $22.5 million of shares of its common stock, at the public offering price, less... Read More
MENLO PARK, Calif. , Jan. 13, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today celebrated long-read sequencing being named Nature Methods' "Method of the Year 2022." Nature Methods had recognized the impact of long-read sequencing in a variety of groundbreaking studies, including those leveraging PacBio technology from the Vertebrate Genome Project,... Read More
PacBio also Releases Preliminary Fourth Quarter 2022 Revenue, Shares Positive Onso Beta Feedback, and Launches the PacBio Compatible Program MENLO PARK, Calif. , Jan. 9, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today it received orders for 76 Revio systems in its fourth quarter ended December 31, 2022 , making it the most successful... Read More
MENLO PARK, Calif. , Jan. 9, 2023 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of highly accurate sequencing solutions, today announced a collaboration with the University of Tokyo , Graduate School of Medicine to study the use of long-read sequencing and novel bioinformatics methods in the hopes of better understanding the genetic causes of certain rare diseases in individuals and cohorts within the Japanese... Read More
MENLO PARK, Calif. , Dec. 28, 2022 /PRNewswire/ -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that it will be participating in the following events at the 41st Annual J.P. Morgan Healthcare Conference: Panel | Multiomics: Markers for Modern Medicine on Tuesday, January 10, 2023 , at approximately 5:15 PM PT . Company presentation and Q&A session on... Read More
Researchers to Investigate Genetic Variants Associated with Rare Pediatric Diseases MENLO PARK, Calif. , Dec. 6, 2022 /PRNewswire/ -- PacBio , a leading developer of high-quality, highly accurate sequencing solutions, today announced its HiFi sequencing technology will be used in a pilot project for the C hildren's R are D isease C ohorts Initiative (CRDC) at Boston Children's Hospital. Boston Children's Hospital researchers... Read More
Cue Biopharma

COPYRIGHT ©2023 HEALTH STOCKS HUB